Urrunaga Nathalie H, Rockey Don C
Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, 22 S. Greene Street, N3W156, Baltimore, MD 21201, USA.
Department of Internal Medicine, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 803, Charleston, SC 29425, USA.
Clin Liver Dis. 2014 May;18(2):389-406. doi: 10.1016/j.cld.2014.01.008.
Portal hypertensive gastropathy (PHG) and colopathy (PHC) are considered complications of portal hypertension. Both entities are clinically relevant because they may cause insidious blood loss or even acute massive gastrointestinal hemorrhage. Endoscopic evaluation is necessary for the diagnosis of PHG and PHC. The existence of different endoscopic criteria for PHG and PHC makes consensus difficult and results in a broad range of reported prevalence. Therapy targeted at reduction of portal pressure and mucosal blood flow has been used to treat acute bleeding; nonselective β-blockers are the most frequently used agents. Further studies are needed to clarify the natural history, pathogenesis, and treatment of PHG and PHC.
门静脉高压性胃病（PHG）和结肠病（PHC）被认为是门静脉高压的并发症。这两种情况在临床上都具有相关性，因为它们可能导致隐匿性失血甚至急性大量胃肠道出血。内镜评估对于PHG和PHC的诊断是必要的。PHG和PHC不同的内镜标准使得达成共识变得困难，导致报道的患病率范围很广。旨在降低门静脉压力和黏膜血流的治疗方法已被用于治疗急性出血；非选择性β受体阻滞剂是最常用的药物。需要进一步研究以阐明PHG和PHC的自然病程、发病机制及治疗方法。
